Elevated expression of HABP1 is a novel prognostic indicator in triple-negative breast cancers

Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
Ji WangDa Pang

Abstract

Hyaluronan-binding protein 1 (HABP1) has been documented to overexpress in several malignancies. The aim of our study is to investigate the expression of HABP1 protein in triple-negative breast cancer (TNBC) and its clinical significance. Using immunohistochemistry, HABP1 expression was evaluated in 139 TNBC specimens. The association between HABP1 expression with clinicopathological parameters was assessed using chi-square test. The survival status of patients was analyzed using the Kaplan-Meier and log-rank tests. Cox regression was used for the multivariate analysis of prognostic factors. The results showed that HABP1 overexpression correlated with higher histological grade (P = 0.004), advanced TNM stage (P = 0.008), greater tumor size (P = 0.016), metastasis of lymph node (P < 0.001), and recurrence (P = 0.040). Furthermore, it indicated that patients with HABP1 overexpression had significantly poorer overall survival (OS) and disease-free survival (DFS) compared with patients (P < 0.001 for both). Multivariate Cox regression analysis revealed that elevated HABP1 expression was an independent prognostic factor for both OS (P = 0.035) and DFS (P = 0.013). In contrast to the effect of HABP1 in TNBCs with lymph node metastasi...Continue Reading

References

Aug 1, 1991·Experimental Cell Research·S Gupta, K Datta
Sep 25, 2001·The Journal of Pathology·A A AlizadehM van de Rijn
Aug 19, 2003·Seminars in Surgical Oncology·S Eva SingletaryUNKNOWN Breast Task Force
May 18, 2004·International Journal of Cancer. Journal International Du Cancer·Daniel B RubinsteinThierry Guillaume
Mar 18, 2006·Apoptosis : an International Journal on Programmed Cell Death·Anupama Kamal, K Datta
Aug 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rebecca DentSteven A Narod
Nov 6, 2007·Clinical Oncology : a Journal of the Royal College of Radiologists·L S Kilburn, UNKNOWN TNT Trial Management Group
Jan 4, 2008·Histopathology·J S Reis-Filho, A N J Tutt
Jun 10, 2008·Cancer Cell·Koji Itahana, Yanping Zhang
Jul 10, 2008·Bioconjugate Chemistry·Geoffrey von MaltzahnSangeeta N Bhatia
Apr 21, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M Elizabeth H HammondAntonio C Wolff
Aug 10, 2013·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Hongyang YuFubin Zhang
Oct 31, 2014·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Jia ZhaoJing Wang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Related Papers

International Journal of Molecular Sciences
Daye ChengYunhui Li
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
Ben-Shun HuJian-Ping Li
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists
Fanling MengGe Lou
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
Meng YangGe Lou
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
Xiao-Yang WuJun-Ying Xu
© 2021 Meta ULC. All rights reserved